BioVentrix has completed patient enrolment in a pilot human clinical trial of its PliCath HF heart failure treatment system.
The PliCath HF system reduces ventricular volume, allowing the heart to pump properly and maintain perfusion to the body without excessive stress on the muscle of the heart wall.
Go deeper with GlobalData
To date, 12 patients have showed an average indexed left ventricular end systolic volume reduction of 31%, with an improvement in ejection fraction.
BioVentrix medical advisor Andrew Wechsler said that the PliCath HF device enables significant left ventricular volume, resulting in the restoration of cardiac function without the risk of cutting into the heart or the need for cardiopulmonary bypass.
